26 Analysts Have This To Say About Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $182.77, with a high estimate of $235.00 and a low estimate of $128.00. Recent analyst actions include several raises in price targets and ratings, reflecting positive sentiment towards the company's financial performance and growth potential.
July 29, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics (NASDAQ:SRPT) has received a mix of bullish and somewhat bullish ratings from 26 analysts over the past three months. The average 12-month price target has increased to $182.77, indicating positive sentiment towards the company's financial performance and growth potential.
The majority of analysts have given bullish or somewhat bullish ratings, and the average price target has increased significantly. This indicates strong positive sentiment towards Sarepta Therapeutics' financial performance and growth potential, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100